iBio, Inc. (IBIO)
-NYSE MKT | Prev Close: | 0.39 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | 0.41 x 1800 |
|---|
| 1y Target Est: | 3.00 |
|---|
| Beta: | 1.08 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 0.38 - 1.70 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 110,665 |
|---|
| Market Cap: | 18.39M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.16 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- IBIO, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, May 20)
- IBIO, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial Statements and ExhibitsEDGAR Online(Wed, May 1)
- iBio, Inc. closes $4.2 million public offering and terminates At-the-market offeringPR Newswire(Mon, Apr 29)
- IBIO, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsEDGAR Online(Tue, Apr 23)
- iBio, Inc. Prices $4.2 Million Public OfferingPR Newswire(Tue, Apr 23)
- iBio files to sell common stock and common stock purchase warrantsat theflyonthewall.com(Mon, Apr 22)
- IBIO, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; TransfEDGAR Online(Mon, Apr 22)
- iBio Passes Commercial Technology Transfer MilestonePR Newswire(Mon, Apr 22)
- iBio, Inc. receives Notice from NYSE MKT Staff that Company currently is not in compliance with an additional Continued Listing StandardPR Newswire(Mon, Apr 22)
- GE Healthcare: Driving Growth Through Alliances And Acquisitionsat Seeking Alpha(Fri, Apr 12)
- GE alliance awarded contract to design new plant-based manufacturing facility in BrazilCNW Group(Tue, Apr 9)
- GE alliance awarded contract to design new plant-based manufacturing facility in BrazilPR Newswire(Tue, Apr 9)
- Flu Stocks For Investors To Considerat Seeking Alpha(Mon, Apr 8)
- iBio Selects Proprietary Recombinant C1 Inhibitor for Clinical DevelopmentPR Newswire(Tue, Mar 26)
- iBio to receive new patent to add to iBioModulator portfolioat theflyonthewall.com(Wed, Mar 13)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 16.52 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | -0.15 |
|---|
| Quarterly EPS Est
(Sep-12)
: | N/A |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
iBio, Inc., a biotechnology company, engages in the development and commercialization of vaccines and therapeutic proteins through its proprietary iBioLaunch platform technology in the United States.
View More 
0.12%